First in Human, Dose Escalation, Dose Expansion Study of AUR105 — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(9 sites)
India
HCG City Cancer Center, Vijayawada, Andhra Pradesh Omega Hospitals, Visakhapatnam, Andhra Pradesh Kailash Cancer Hospital and Research Centre, Vadodara, Gujarat Krupamayi Hospital, Aurangabad, Maharashtra Moraya Multi-Speciality Hospital, Pune, Maharasthra Sparsh Hospital and Critical Care, Bhubaneswar, Odisha All India Institute of Medical Sciences, Bhubaneswar, Odisha IMS&SUM Hospital, Bhubaneswar ALL India Institute of medical Scieneces, New Delhi Last updated January 2024